Effects of brewer's yeast extract on growth performance and health of juvenile pikeperch Sander lucioperca (L.)

Juvenile European pikeperch, Sander lucioperca, were fed commercial feed (group C) or experimental feed supplemented with NuPro® nucleotide‐rich Saccharomyces cerevisiae yeast protein (extract obtained through a cell wall removal process) in doses of 20, 40 or 60 g kg−1 feed (groups N2, N4, N6) for...

Full description

Saved in:
Bibliographic Details
Published in:Aquaculture nutrition 2012-08, Vol.18 (4), p.457-464
Main Authors: JARMOŁOWICZ, S., ZAKĘŚ, Z., SIWICKI, A., KOWALSKA, A., HOPKO, M., GŁĄBSKI, E., DEMSKA-ZAKĘŚ, K., PARTYKA, K.
Format: Article
Language:English
Subjects:
brewer's yeast
Freshwater
growth
Immune response
Nucleotide
Saccharomyces cerevisiae
Sander lucioperca
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Juvenile European pikeperch, Sander lucioperca, were fed commercial feed (group C) or experimental feed supplemented with NuPro® nucleotide‐rich Saccharomyces cerevisiae yeast protein (extract obtained through a cell wall removal process) in doses of 20, 40 or 60 g kg−1 feed (groups N2, N4, N6) for 8 weeks. Growth, non‐specific immunity parameters, histological structure of the liver and intestine, proximate whole‐body composition and blood biochemical parameters were assayed. It was noted that brewer’s yeast extract has immunomodulatory proprieties. NuPro® in doses of 40 and 60 g kg−1 feed strongly stimulated non‐specific (innate) cellular and humoral immunity in pikeperch. The experimental feed did not have a significant impact on pikeperch growth (P > 0.05). The proximate composition of the fish bodies and the hepatosomatic and viscerosomatic (VSI) indices were also not affected, which indicated that the tested diets had no negative impact on the metabolism or deposition of nutrients in fish tissues. The lower levels of transaminases AST and ALT, which were noted in the groups with the two highest doses of NuPro® (P 
ISSN:1353-5773
1365-2095
DOI:10.1111/j.1365-2095.2011.00915.x